Cargando…

Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom

INTRODUCTION: EHealth holds tremendous promise for enhancing drug safety initiatives known as risk minimization programs. Little is known, however, regarding the scope and quality of existing risk minimization websites. METHODS: Two publicly accessible repositories, REMS@FDA [1] and Electronic Medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Meredith Y., Frise, Sarah, Feron, Jane, Marshall, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933380/
https://www.ncbi.nlm.nih.gov/pubmed/35247194
http://dx.doi.org/10.1007/s40264-022-01165-4
_version_ 1784671637370568704
author Smith, Meredith Y.
Frise, Sarah
Feron, Jane
Marshall, Ryan
author_facet Smith, Meredith Y.
Frise, Sarah
Feron, Jane
Marshall, Ryan
author_sort Smith, Meredith Y.
collection PubMed
description INTRODUCTION: EHealth holds tremendous promise for enhancing drug safety initiatives known as risk minimization programs. Little is known, however, regarding the scope and quality of existing risk minimization websites. METHODS: Two publicly accessible repositories, REMS@FDA [1] and Electronic Medicines Compendium [2], were reviewed to identify all regulatorily approved risk minimization programs in the United States (US) and United Kingdom (UK) with websites. Website quality was evaluated using the Enlight Quality Assessment tool, a psychometrically validated instrument that addresses seven quality domains. RESULTS: Ninety-three websites were identified: 59 for healthcare professionals (7 UK/52 US), and 34 for patients (5 UK/29 US). The websites functioned chiefly as archives for electronic copies of educational materials; a subset (31/93) had additional features. Mean quality ratings for Usability (mean 4.70, SD 0.59), Visual Design (mean 4.03, SD 0.87) and Content (mean 4.31, SD 0.82) were good. General Subjective Evaluation was fair (mean 3.15, SD 1.21). Mean scores for Therapeutic Alliance and Therapeutic Persuasiveness were poor (mean 2.62, SD 1.47; and mean 2.50, SD 1.48, respectively); those for User Engagement were very poor (mean 2.25, SD 1.03). No differences were found by target audience but several were identified based on region. CONCLUSIONS: Risk minimization websites are easy to navigate and well organized. Few, however, incorporate eHealth design elements that facilitate user engagement, build therapeutic alliance and exert therapeutic persuasiveness. Such elements can enhance program uptake and effectiveness. Results highlight opportunities for improving the quality of risk minimization websites and their ability to bridge pharmaceutical and healthcare systems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40264-022-01165-4.
format Online
Article
Text
id pubmed-8933380
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89333802022-04-01 Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom Smith, Meredith Y. Frise, Sarah Feron, Jane Marshall, Ryan Drug Saf Original Research Article INTRODUCTION: EHealth holds tremendous promise for enhancing drug safety initiatives known as risk minimization programs. Little is known, however, regarding the scope and quality of existing risk minimization websites. METHODS: Two publicly accessible repositories, REMS@FDA [1] and Electronic Medicines Compendium [2], were reviewed to identify all regulatorily approved risk minimization programs in the United States (US) and United Kingdom (UK) with websites. Website quality was evaluated using the Enlight Quality Assessment tool, a psychometrically validated instrument that addresses seven quality domains. RESULTS: Ninety-three websites were identified: 59 for healthcare professionals (7 UK/52 US), and 34 for patients (5 UK/29 US). The websites functioned chiefly as archives for electronic copies of educational materials; a subset (31/93) had additional features. Mean quality ratings for Usability (mean 4.70, SD 0.59), Visual Design (mean 4.03, SD 0.87) and Content (mean 4.31, SD 0.82) were good. General Subjective Evaluation was fair (mean 3.15, SD 1.21). Mean scores for Therapeutic Alliance and Therapeutic Persuasiveness were poor (mean 2.62, SD 1.47; and mean 2.50, SD 1.48, respectively); those for User Engagement were very poor (mean 2.25, SD 1.03). No differences were found by target audience but several were identified based on region. CONCLUSIONS: Risk minimization websites are easy to navigate and well organized. Few, however, incorporate eHealth design elements that facilitate user engagement, build therapeutic alliance and exert therapeutic persuasiveness. Such elements can enhance program uptake and effectiveness. Results highlight opportunities for improving the quality of risk minimization websites and their ability to bridge pharmaceutical and healthcare systems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40264-022-01165-4. Springer International Publishing 2022-03-05 2022 /pmc/articles/PMC8933380/ /pubmed/35247194 http://dx.doi.org/10.1007/s40264-022-01165-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Smith, Meredith Y.
Frise, Sarah
Feron, Jane
Marshall, Ryan
Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom
title Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom
title_full Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom
title_fullStr Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom
title_full_unstemmed Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom
title_short Improving the Safety of Medicines via Digital Technology: An Assessment of the Scope and Quality of Risk Minimization Websites in the United States and United Kingdom
title_sort improving the safety of medicines via digital technology: an assessment of the scope and quality of risk minimization websites in the united states and united kingdom
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933380/
https://www.ncbi.nlm.nih.gov/pubmed/35247194
http://dx.doi.org/10.1007/s40264-022-01165-4
work_keys_str_mv AT smithmeredithy improvingthesafetyofmedicinesviadigitaltechnologyanassessmentofthescopeandqualityofriskminimizationwebsitesintheunitedstatesandunitedkingdom
AT frisesarah improvingthesafetyofmedicinesviadigitaltechnologyanassessmentofthescopeandqualityofriskminimizationwebsitesintheunitedstatesandunitedkingdom
AT feronjane improvingthesafetyofmedicinesviadigitaltechnologyanassessmentofthescopeandqualityofriskminimizationwebsitesintheunitedstatesandunitedkingdom
AT marshallryan improvingthesafetyofmedicinesviadigitaltechnologyanassessmentofthescopeandqualityofriskminimizationwebsitesintheunitedstatesandunitedkingdom